Sexual Orientation and Gender Identity (SOGI) data remains largely absent from clinical research, despite its growing relevance to scientific rigor, regulatory readiness, and long-term market success. This case study outlines why integrating SOGI data is not simply a matter of inclusion, but a strategic imperative for modern clinical development. Drawing on epidemiology, regulatory trends, and industry practice, it presents a clear business, medical, and global rationale for action—demonstrating how representative data strengthens evidence generation, mitigates risk, and supports more effective, patient-responsive medicines.
Download the SOGI Business Case to review the evidence, regulatory context, and practical insights that outline why inclusive data collection matters—and how it can be implemented responsibly and effectively.
